Avantor unveils $500M share buyback initiative
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 29 2025
0mins
Should l Buy AVTR?
Share Repurchase Program: Avantor's Board has authorized a new $500 million share repurchase program, reflecting confidence in the company's growth and profitability potential.
Commitment to Shareholders: CEO Ligner expresses strong belief in the company's future performance and is implementing changes aimed at delivering positive results for shareholders.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AVTR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AVTR
Wall Street analysts forecast AVTR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVTR is 12.30 USD with a low forecast of 8.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
2 Buy
9 Hold
2 Sell
Hold
Current: 10.790
Low
8.00
Averages
12.30
High
17.00
Current: 10.790
Low
8.00
Averages
12.30
High
17.00
About AVTR
Avantor, Inc. is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. The Company’s segments include Laboratory Solutions and Bioscience Production. Within its segments, it sells materials and consumables, equipment and instrumentation and services and specialty procurement to customers in the biopharma and healthcare, education and government and advanced technologies and applied materials industries. Materials and consumables include ultra-high purity chemicals and reagents, lab products and supplies, highly specialized formulated silicone materials, customized excipients, and others. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, and others. Services and specialty procurement include onsite lab and production, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Redwire Contract: Redwire CEO Peter Cannito highlighted that the company's contract with the Department of Defense underscores its strength in space and defense technologies, which could yield strong returns for investors by 2026.
- Investor Events Preview: Redwire will participate in several investor events, including the Raymond James Institutional Investors Conference on March 2, the Morgan Stanley Technology, Media, and Telecom Conference on March 3, the DB Internet & Telecom Conference on March 10, and the New Street BCG Connectivity Conference on March 26, drawing investor attention.
- Lumen Watch: Lumen is positioned as a stock to watch due to its upcoming earnings report and multiple investor events, which could significantly impact its stock performance.
- Market Dynamics Tracking: Benzinga's weekly Stock Whisper Index provides investors with opportunities to identify undervalued and emerging stocks, assisting them in navigating information overload to uncover potential investment opportunities.
See More
- Fiduciary Duty Investigation: Kuehn Law, PLLC is investigating whether Avantor, Inc. executives breached their fiduciary duties to shareholders, with allegations that could impact corporate governance and shareholder confidence.
- False Competitive Positioning: A federal securities lawsuit claims insiders at Avantor failed to disclose that the company's competitive positioning was weaker than publicly represented, potentially leading to investor misjudgment regarding the company's prospects.
- Negative Competitive Pressures: Avantor is reportedly experiencing adverse effects from increased competition, and the failure to disclose this information may result in shareholder losses in investment decisions, affecting the company's stock performance.
- Shareholder Rights Protection: Kuehn Law urges shareholders to contact attorneys promptly to protect their rights, emphasizing the importance of participation, which could influence future shareholder litigation and corporate governance structures.
See More
- Earnings Release Schedule: Avantor will release its Q4 and full-year 2025 financial results before the market opens on February 11, 2026, demonstrating the company's commitment to transparency and investor communication.
- Conference Call Timing: A conference call will take place on the same day at 8:00 a.m. Eastern Standard Time, aimed at providing in-depth discussions of the financial results to bolster market confidence.
- Webcast Availability: The session will be available via live audio webcast on Avantor's investor section, with a replay accessible for 30 days, ensuring that investors unable to attend live can still receive the information.
- Global Customer Base: Avantor serves over 300,000 customer locations in 180 countries, highlighting its leadership position in the life sciences and advanced technology sectors.
See More
- Earnings Release Schedule: Avantor will release its Q4 and full-year 2025 financial results before the market opens on February 11, 2026, demonstrating the company's commitment to transparency and investor communication.
- Conference Call Timing: A conference call will take place on the same day at 8:00 a.m. Eastern Standard Time, aimed at providing in-depth discussions of the financial results to bolster market confidence.
- Live Webcast Availability: Investors can listen to the live audio webcast of the session via the Investor section of Avantor's website, reflecting the company's modernization in information dissemination.
- Replay Service: A replay of the webcast will be available for 30 days post-event, ensuring that investors who cannot attend live can still access critical information, further enhancing information accessibility.
See More

- Conference Presentation: Avantor's CEO Emmanuel Ligner is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at approximately 8:15 a.m. PST, highlighting the company's leadership in the life sciences sector.
- Investor Engagement Opportunity: The presentation will be streamed live on Avantor's website, allowing global investors to stay updated on the company's latest developments, thereby enhancing investor relations.
- Replay Availability: A replay of the webcast will be accessible for 30 days post-event, ensuring that investors who miss the live session can still access critical information, which increases transparency and engagement.
- Company Overview: Avantor is a leading life science tools company providing mission-critical products and services to the life sciences and advanced technology sectors, serving over 300,000 customer locations across 180 countries, underscoring its significance in the industry.
See More

- Conference Appearance: Avantor CEO Emmanuel Ligner is set to present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at approximately 8:15 a.m. Pacific Standard Time, showcasing the company's leadership in the life sciences sector.
- Investor Engagement: The session will be live-streamed via Avantor's investor section on its website, facilitating real-time updates for global investors and enhancing interaction and transparency with stakeholders.
- Replay Availability: A replay of the webcast will be accessible for 30 days post-event, ensuring that investors who cannot attend live can still access critical information, thereby broadening and deepening the company's information dissemination.
- Industry Impact: As a key provider of mission-critical products and services in the life sciences and advanced technology sectors, Avantor's participation will further solidify its influence in the industry and potentially attract more investor interest in its future growth prospects.
See More








